Ardelyx(US:ARDX)2025-10-30 20:09Revenue Performance - Q3 2025 product revenue reached $105.5 million, reflecting a 15% year-over-year growth[1] - IBSRELA generated $78.2 million in Q3 revenue, marking a 92% year-over-year increase and a 20% increase compared to Q2 2025; full-year 2025 revenue guidance raised to $270-275 million[5] - XPHOZAH revenue was $27.4 million in Q3 2025, up 9% from Q2 2025, driven by increased demand prescriptions and total dispenses[6] - Total revenue for Q3 2025 was $110.3 million, compared to $98.2 million in Q3 2024, primarily due to increased IBSRELA revenue[12] - Total revenues for the three months ended September 30, 2025, were $110.329 million, an increase of 12.5% compared to $98.241 million for the same period in 2024[31] - Total product sales, net for the three months ended September 30, 2025, reached $105.515 million, up 14.6% from $92.090 million in the prior year[31] - The total product supply revenue for the three months ended September 30, 2025, was $0, down from $5.322 million in the same quarter of 2024[31] Expenses - Research and development expenses for Q3 2025 were $18.1 million, up from $15.3 million in Q3 2024, reflecting pipeline expansion activities[12] - Selling, general and administrative expenses were $83.6 million in Q3 2025, an increase from $65.0 million in Q3 2024[12] - Research and development expenses for the three months ended September 30, 2025, were $18.067 million, an increase of 17.4% from $15.310 million in the same quarter of 2024[31] - Selling, general and administrative expenses for the three months ended September 30, 2025, totaled $83.612 million, a rise of 28.6% compared to $64.970 million in the prior year[31] - The total cost of goods sold for the three months ended September 30, 2025, was $3.982 million, a decrease of 74.7% from $15.728 million in the same quarter of 2024[31] - The total operating expenses for the nine months ended September 30, 2025, were $299.493 million, an increase of 35.4% from $221.269 million for the same period in 2024[31] Net Loss - Net loss for Q3 2025 was $1.0 million, compared to a net loss of $0.8 million in Q3 2024[12] - The net loss for the three months ended September 30, 2025, was $969,000, compared to a net loss of $809,000 for the same period in 2024[31] - The company reported a loss before provision for income taxes of $867,000 for the three months ended September 30, 2025, compared to a loss of $766,000 in the same period of 2024[31] - The company’s net loss per share for the nine months ended September 30, 2025, was $0.25, compared to $0.19 for the same period in 2024[31] Future Developments - The company announced the development of RDX10531, a next-generation NHE3 inhibitor, with an IND submission planned for 2026[7] Cash Position - As of September 30, 2025, total cash, cash equivalents, and short-term investments were $242.7 million, compared to $250.1 million at the end of 2024[12] Events and Presentations - The company had a significant presence at the 2025 Annual Scientific Meeting for the American College of Gastroenterology, presenting three posters and sponsoring a Product Theater[12]